fulllogo_transparent_nobuffer Aanastra.png
Aanastra Inc to Present Multiple Posters on RNA Therapeutics at the American Association for Cancer Research (AACR) Annual Meeting 2024
03 avr. 2024 06h30 HE | Aanastra Inc
Aanastra to present its RNA peptide therapeutics technology at AACR conference
Aprea logo 445pt.png
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
08 sept. 2022 08h00 HE | Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11 août 2022 16h15 HE | Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Aprea logo 445pt.png
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations
15 mars 2022 16h15 HE | Aprea Therapeutics
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022
06 janv. 2022 08h00 HE | Aprea Therapeutics
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting
14 déc. 2021 08h00 HE | Aprea Therapeutics
BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH...
Aprea logo 445pt.png
Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Malignancies
09 déc. 2021 08h00 HE | Aprea Therapeutics
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations
08 nov. 2021 16h15 HE | Aprea Therapeutics
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea logo 445pt.png
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
14 sept. 2021 08h00 HE | Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea logo 445pt.png
Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations
12 août 2021 16h15 HE | Aprea Therapeutics
BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...